Adipromin is a revolutionary weight loss supplement that is neither a stimulant nor an appetite suppressant. Unlike traditional weight loss supplements, Adipromin does not interfere with the absorption of fat or sugar and does not create a sense of fullness.
Based on preclinical research, Adipromin works through a dual modality:
Modulation of Adipogenesis (creation of new fat cells) and Lipolysis (fat breakdown): Adipromin has been shown to inhibit lipid accumulation in adipocytes, slows the maturation of these cells, reduces intracellular triglyceride (fat) content and demonstrably down-regulates transcription factors PPAR‐gamma and C/EBP.†* (genetic material that replicates fat cells)
Increases Resting Energy Expenditure (REE): Two preclinical animal studies† and a human clinical trial have shown that Adipromin can increase resting energy expenditure. This metabolic increase is driven by higher production levels of thermogenic markers (AMPKα, PGC1α, and UCP1) and lipolytic (HSL) proteins†.(these are markers associated with increased metabolism)
The efficacy of Adipromin for weight loss has been demonstrated in two randomized, double-blind, placebo-controlled clinical trials (RCTs) which have been published in well-respected medical journals.
In one of these trials, healthy overweight subjects using Adipromin in conjunction with a diet and exercise plan showed significant reductions in body weight, body mass index (BMI), waist circumference, and hip circumference compared to placebo. Additionally, those taking Adipromin showed significant improvements in blood lipid profiles and certain hormones related to appetite and fat storage.
The outstanding second Randomized Control Trial (RCT) involving Adipromin, which was published in a highly respected medical journal, involved healthy overweight participants (n=140). This 16-week study compared Adipromin's effects, used along with an 1800 kcal/day diet and a walking plan of 30 minutes for 5 times a week, to a placebo group following the same diet and walking regime.
Key findings from the study are outlined below:
* Participants using Adipromin showed significant reductions in body weight (average loss of 11.82 pounds compared with 1.92 pounds in the placebo group; p < 0.0001) and Body Mass Index (BMI) (a decrease of 2.05 kg/m2 compared to a decrease of 0.34 kg/m2 in the placebo group, p < 0.0001).
* Waist circumference was significantly lower in participants using Adipromin (average reduction of 2.12 inches versus a reduction of 0.67 inches in the placebo group; p < 0.0001) as was hip circumference (average reduction of 1.77 inches compared to a reduction of 0.47 inches in the placebo group; p < 0.0001).
* Blood lipid profiles, including triglyceride levels, showed a statistically significant improvement in the Adipromin group compared to the placebo group (p < 0.0001).
* Concentrations of serum adiponectin and serum ghrelin improved in the Adipromin group compared to the placebo group (p = 0.0071 and p = 0.0568 respectively).
* A post-hoc analysis revealed that Adipromin users had over a 37% reduction in their Visceral Adiposity Index (VAI), while the VAI of those in the placebo group increased slightly.
A third RCT, set to be published in 2022, shows that Adipromin has a significant impact on Resting Metabolic Rate (RMR) without any stimulant effects.
Adipromin provides a unique set of holistic benefits for weight management and cardiometabolic health that includes:
Adipromin has been shown to be safe and well-tolerated in both preclinical and clinical studies.
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
†These modes of action for Adipromin were demonstrated in pre-clinical research, not in humans.
 Dixit K, et al. Efficacy of a novel herbal formulation for weight loss demonstrated in a 16-week randomized, double-blind, placebo-controlled clinical trial with healthy overweight adults. Diabetes Obes Metab. 2018;20(11):2633-2641. doi:10.1111/dom.13443